Pro Medicus (ASX:PME) share price rockets 16% on earnings beat

This healthcare technology company’s shares were the best performers on the ASX 200 today…
The post Pro Medicus (ASX:PME) share price rockets 16% on earnings beat appeared first on The Motley Fool Australia. –

The Pro Medicus Limited (ASX: PME) share price was the standout performer on the S&P/ASX 200 Index (ASX: XJO) on Thursday.

The healthcare technology company’s shares were up as much as 16.5% to a record high of $65.90 before finishing the day up 15.5%.

The Pro Medicus share price is now up 86% since the start of the year.

Why did the Pro Medicus share price rocket higher?

Investors were bidding the Pro Medicus share price higher following the release of an impressive full year result this morning.

For the 12 months ended 30 June, the company reported a 19.5% increase in revenue to $67.9 million and a 43% jump in earnings before interest and tax (EBIT) to $42.7 million.

This was driven by the implementation of a series of major contract wins and further operating leverage.

Also giving the Pro Medicus share price a boost were comments by management. It advised that although FY 2021 was a record year on new contracts, its pipeline remains very healthy in respect to quality and quantity.

How does this compare to expectations?

Although its revenue fell a touch short of the market’s expectation of $70 million, this was largely due to foreign exchange headwinds.

Positively, despite its revenue missing, its EBIT was ahead of the consensus estimate of $41.6 million thanks to stronger than expected margin expansion.

Goldman Sachs has commented on the result. It said: “Group revenue of $67.9m fell -3% short of consensus expectations as revenue growth for the core PACS segment of +18% (to $55.3m) fell short of our expectations of +26% (to $59.0m). However, on a constant currency basis, revenue grew +30% to $74.0m, likely explaining the majority/all of the miss.”

“Furthermore, EBIT grew +43%, coming in +3% ahead of expectations, as margins increased +1,036bps (vs. cons +690bps). Net income grew +34% to $30.9m and period-end cash grew +42% to $61.8m, and the company remains debt-free.”

Is it too late to invest?

Goldman Sachs currently has a neutral rating and $55.60 price target on its shares. This compares to the current Pro Medicus share price of $65.35.

However, it has yet to update its model to reflect this result. So, there’s a chance in the coming days it could lift its price target higher. Investors may want to stay tuned for that one.

The post Pro Medicus (ASX:PME) share price rockets 16% on earnings beat appeared first on The Motley Fool Australia.

Should you invest $1,000 in Pro Medicus right now?

Before you consider Pro Medicus, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

ASX 200 drops, BHP falls, Pro Medicus soars

Here are the top 10 ASX 200 shares today

Passive income your thing? These 3 ASX dividend shares just declared bigger payments

Which ASX 300 shares are the biggest winners and losers mid-week?

Why Beach, Domain, Domino’s, & Pro Medicus shares are storming higher

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!